EB-18 Molecule: Higher Tumor Suppression and Specific Toxicity in Prostate Cancer

A novel small molecule designated as EB-18 reduces tumor progression and volume in castration-resistant prostate cancer models more effectively than standard chemotherapeutic agents at identical doses.

During the preclinical trials, mice carrying castration-resistant tumors received intraperitoneal administration of EB-18 twice a week for five weeks. This treatment regime reduced disease progression and tumor volume to a greater extent than established reference drugs such as 5-fluorouracilo or docetaxel administered at the same doses. The therapy triggered a decrease in the expression of the proliferation marker Ki-67 and lowered levels of a DNA repair-related protein, which increased the number of cancer cells entering programmed cell death, or apoptosis.

In terms of safety parameters, EB-18 left serum metrics for hepatic, renal, and metabolic function unaltered. Unlike typical chemotherapeutic agents, it avoided causing myelosuppression, leaving leukocyte and platelet counts stable. However, researchers observed a significant drop in hemoglobin levels alongside an elevated red cell distribution width, pointing toward measurable toxicity affecting red blood cell homeostasis.

Laboratory Testing in Three-Dimensional Organoids

The antitumoral activity of EB-18 was further validated in three-dimensional organoids derived directly from prostate cancer patients. In these models, tumor suppression exceeded the efficacy observed with standard reference drugs docetaxel, cabazitaxel, or mitoxantrone. Palma Rocchi, co-director of the study, noted that the reduction in cell viability achieved by EB-18 in spheroids from an androgen receptor-independent cell line reached 93 percent, compared to values ranging between 46 percent and 77 percent for conventional therapies.

The compound maintained its activity in multi-resistant cells of this cancer type as well as across multiple other tumor types, including triple-negative breast cancer, though higher concentrations were required for those effects. Rocchi stated that the wide therapeutic spectrum of the potential drug stems from its capability to simultaneously interfere with stress response pathways, oncogenic survival signaling, and DNA repair mechanisms.